

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

14
JMJ
03/03/02
jc997 U.S. PTO
10/099830
03/13/02

Applicants: Philip John Burke and Richard John Knox

Serial No.: Continuation of 09/445,865

Express Mail Label
No. EL 778 572 141 US

Filed: March 13, 2002

Date of Deposit: March 13, 2002

For: THERAPEUTIC SYSTEMS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including nine (9) pages of Form PTO-1449. The documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/445,865, filed February 11, 2000, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

Continuation of U.S.S.N. 09/445,865
 Filed: March 13, 2002
Information Disclosure Statement
 Express Mail Label No.: EL 778 572 141 US
 Date of Deposit: March 13, 2002

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,440,859	04-03-1984	Rutter, et al.	435/172
4,530,901	07-23-1985	Weissmann	435/708
4,582,800	04-15-1986	Crowl	435/70
4,677,063	06-30-1987	Mark, et al.	435/68
4,678,751	07-07-1987	Goeddel	435/243
4,704,362	11-03-1987	Itakura, et al.	435/253
4,710,463	12-01-1987	Murray	435/68
4,757,006	07-12-1988	Toole, Jr., et al.	435/70
4,766,075	08-23-1988	Goeddel, et al.	435/240.2
4,810,648	03-07-1989	Stalker	435/191

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0 251 744 A2	01-07-1988	Delta Biotechnology Ltd.	EP
0 258 067 A2	03-02-1988	Delta Biotechnology Ltd.	EP
0 302 473 A2	02-08-1989	Bristol-Myers Co.	EP
0 415 731 A2	03-06-1991	The Wellcome Foundation Ltd.	EP
WO 88/07378 A1	10-06-1988	Cancer Research Campaign Technology Ltd.	PCT
WO 89/10140 A1	11-02-1989	Cancer Research Campaign Technology Ltd.	PCT
WO 90/01063 A1	02-08-1990	Delta Biotechnology Ltd.	PCT
WO 91/09867 A1	07-11-1991	Imperial Cancer Research Technology Ltd.	PCT
WO 91/11201 A1	08-07-1991	Imperial Cancer Research Technology Ltd.	PCT
WO 93/08288 A1	04-29-1993	Cancer Research Campaign Technology Ltd.	PCT
WO 93/13805 A1	07-22-1993	Bagshawe	PCT
WO 93/13806 A1	07-22-1993	Bagshawe	PCT
WO 95/12678 A1	05-11-1995	Cancer Research Campaign Technology Ltd.	PCT
WO 97/07097 A1	02-27-1997	Auckland Division Cancer Society of New Zealand	PCT
WO 97/20580 A1	06-12-1997	AEPACT, Ltd.	PCT
WO 97/24143 A1	07-10-1997	AEPACT, Ltd.	PCT
WO 97/24143 A1	07-10-1997	AEPACT, Ltd.	PCT
WO 98/22577 A1	05-28-1998	Masucci	PCT

WO 98/24478 A2 06-11-1998 AEPACT, Ltd.

PCT

Publications

ANLEZARK, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from *Escherichia coli*--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)," *Biochem. Pharmacol.* 1992 44(12):2289-95.

BETTER, et al., "Escherichia coli secretion of an active chimeric antibody fragment," *Science* 240(4855):1041-43 (1988).

BIRD, et al., "Single-chain antigen-binding proteins," *Science* 242(4877):423-26 (1988).

BISCHOFF, et al., "An adenovirus mutant that replicates selectively in p53-deficient human tumor cells," *Science* 274(5286):373-76 (1996).

BOLAND, et al., "The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)," *Biochem. Pharmacol.* 41(6-7):867-75 (1991).

BRADL, et al., "Malignant melanoma in transgenic mice," *Proc. Natl. Acad. Sci. U. S. A.* 88(1):164-68 (1991).

BRAWER, "Prostate specific antigen. A review," *Acta. Oncol.* 30(2):161-68 (1991).

CHEN, et al., "Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in *Escherichia coli* and mutagenesis in vitro at Arg-177," *Biochem. J.* 284 (Pt 3):855-60 (1992).

CHEN, et al., "Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse," *J. Biol. Chem.* 272(3):1437-39 (1997).

CLARK, et al., "Role of the Bp35 cell surface polypeptide in human B-cell activation," *Proc. Natl. Acad. Sci. U. S. A.* 82(6):1766-70 (1985).

CONNORS & WISSON, "Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity," *Nature* 210(38):866-67 (1966).

CORVALAN & SMITH, "Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," *Cancer Immunol. Immunother.* 24(2):127-32 (1987).

Continuation of U.S.S.N. 09/445,865
Filed: March 13, 2002
Information Disclosure Statement
Express Mail Label No.: EL 778 572 141 US
Date of Deposit: March 13, 2002

CORVALAN, et al., "Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," *Cancer Immunol. Immunother.* 24(2):133-37 (1987).

CORVALAN, et al., "Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody," *Cancer Immunol. Immunother.* 24(2):138-43 (1987).

COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," *Proc. Natl. Acad. Sci. U. S. A.* 89(13):6094-98 (1992).

COUSSENS, et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neuroncogene," *Science* 230(4730):1132-39 (1985).

CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," *Science* 256(5063):1550-52 (1992).

CURIEL, "Adenovirus facilitation of molecular conjugate-mediated gene transfer," *Prog. Med. Virol.* 40:1-18 (1993).

DERMER, "Another Anniversary for the War on Cancer," *Bio/Technology* 12:230 (1994).

DRABEK, et al., "The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954," *Gene Ther.* 4(2):93-100 (1997).

FRESHNEY, *Culture of Animal Cells: A Manual of Basic Technique*, Alan R. Liss, Inc., page 4, (New York, 1983).

FRIEDLOS, et al., "Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity," *Biochem. Pharmacol.* 44(9):1739-43 (1992).

FRIEDLOS, et al., "Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)," *Biochem. Pharmacol.* 44(1):25-31 (1992).

FRIEDLOS & KNOX, "Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system," *Biochem. Pharmacol.* 44(4):631-35 (1992).

GILLILAND, et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," *Proc. Natl. Acad. Sci. U. S. A.* 85(20):7719-23 (1988).

Continuation of U.S.S.N. 09/445,865
Filed: March 13, 2002
Information Disclosure Statement
Express Mail Label No.: EL 778 572 141 US
Date of Deposit: March 13, 2002

GREEN, et al., "Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the *E. coli* nitroreductase gene," *Cancer Gene Ther.* 4(4):229-38 (1997).

GURA, "Systems for Identifying New Drugs are Often Faulty," *Science* 278:1041-42 (1997).

HARWOOD, et al., "Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumour xenograft," *Eur. J. Cancer Clin. Oncol.* 21(12):1515-22 (1985).

HELLSTRÖM, et al., "Monoclonal mouse antibodies raised against human lung carcinoma," *Cancer Res.* 46(8):3917-23 (1986).

HURRELL, "Monoclonal Hybridoma Antibodies: Techniques and Applications," (CRC Press.

HUSTON, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*," *Proc. Natl. Acad. Sci. U. S. A.* 85(16):5879-83 (1988).

JACKSON, et al., "The tyrosinase-related protein-1 gene has a structure and promoter sequence very different from tyrosinase," *Nucleic Acids Res.* 19(14):3799-804 (1991).

JAISWAL, "Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression," *J. Biol. Chem.* 269(20):14502-08 (1994).

JAISWAL, "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6," *Biochemistry*. 29(7):1899-906 (1990).

KHAN & ROSS, "Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships," *Chem. Biol. Interact.* 1(1):27-47 (1969).

KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," *Cancer Metastasis Rev.* 12(2):195-212 (1993).

KNOX, et al., "Virtual cofactors for an *Escherichia coli* nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," *Biochem. Pharmacol.* 49(11):1641-47 (1995).

Continuation of U.S.S.N. 09/445,865
Filed: March 13, 2002
Information Disclosure Statement
Express Mail Label No.: EL 778 572 141 US
Date of Deposit: March 13, 2002

KNOX, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an *Escherichia coli* nitroreductase and Walker DT diaphorase," *Biochem. Pharmacol.* 44(12):2297-301 (1992).

KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," *Cell Struct. Funct.* 16(6):503-10 (1991).

LAEMMLI, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," *Nature* 227(259):680-5 (1970).

LEDLEY, "Nonviral gene therapy: the promise of genes as pharmaceutical products," *Hum. Gene Ther.* 6(9):1129-44 (1995).

LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide," *J. Biol. Chem.* 237:2981-87 (1962).

LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," *Biochem. and Biophys. Res. Comm.* 4:208-13 (1961).

LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic hydrocarbons," *Biochem. Pharmacol.* 6:53-54 (1961).

LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," *Biochem. Biophys. Res. Commun.* 161(3):1151-9 (1989).

MARTIN & PAPAHAJOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting," *J. Biol. Chem.* 257(1):286-8 (1982).

MAUGER, et al., "Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme," *J. Med. Chem.* 37(21):3452-58 (1994).

MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," *Gene Ther.* 2(9):660-68 (1995).

MILLER & VILE, "Targeted vectors for gene therapy," *FASEB J.* 9(2):190-99 (1995).

MORRISON, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," *Proc. Natl. Acad. Sci. U. S. A.* 81(21):6851-55 (1984).

Continuation of U.S.S.N. 09/445,865
Filed: March 13, 2002
Information Disclosure Statement
Express Mail Label No.: EL 778 572 141 US
Date of Deposit: March 13, 2002

NÄSSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice," *Cancer Res.* 52(3):646-53 (1992).

NEUBERGER, et al., "Recombinant antibodies possessing novel effector functions," *Nature* 312(5995):604-08 (1984).

O'SULLIVAN, et al., "Comparison of two methods of preparing enzyme-antibody conjugates: application of these conjugates for enzyme immunoassay," *Anal. Biochem.* 100(1):100-08 (1979).

QUINN, "Studies on CB1954 and its analogues," A thesis submitted for the degree of Doctor of Philosophy to the University of London, 1996.

RIEGMAN, et al., "Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene," *Biochem. Biophys. Res. Commun.* 159(1):95-102 (1989).

SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase," *Science* 239(4839):487-91 (1988).

SAMBROOK, et al., Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor:New York (1989).

SCHREWE, et al., "Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression," *Mol. Cell. Biol.* 10(6):2738-48 (1990).

SHARMA, et al., "Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model," *Br. J. Cancer.* 61(5):659-62 (1990).

SHERWOOD, "Advanced drug delivery reviews: enzyme prodrug therapy," *Adv. Drug Del. Rev.* 22:269-88 (1996).

SKERRA, et al., "Assembly of a functional immunoglobulin Fv fragment in Escherichia coli," *Science* 240(4855):1038-41 (1988).

TROWELL, "The cytoidal action of mitotic poisons on lymphocytes *in vitro*," *Biochemical Pharmacology* 5:53-63 (1960).

WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," *Proc. Natl. Acad. Sci. U. S. A.* 87(9):3410-14 (1990).

WARD, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," *Nature* 341(6242):544-46 (1989).

Continuation of U.S.S.N. 09/445,865
Filed: March 13, 2002
Information Disclosure Statement
Express Mail Label No.: EL 778 572 141 US
Date of Deposit: March 13, 2002

WHISSON & CONNORS, "Cure of mice bearing advanced plasma cell tumours with aniline mustard," *Nature* 206(985):689-91 (1965).

WINTER & MILSTEIN, "Man-made antibodies," *Nature* 349(6307):293-99 (1991).

WU, et al., "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase," *Arch. Biochem. Biophys.* 347(2):221-28 (1997).

ZOLA, "Monoclonal Antibodies: A manual of techniques," (CRC Press, 1988).

Continuation of U.S.S.N. 09/445,865
Filed: March 13, 2002
Information Disclosure Statement
Express Mail Label No.: EL 778 572 141 US
Date of Deposit: March 13, 2002

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: March 13, 2002

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

Continuation of U.S.S.N. 09/445,865
Filed: March 13, 2002
Information Disclosure Statement
Express Mail Label No.: EL 778 572 141 US
Date of Deposit: March 13, 2002

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this paper and any documents referred to as attached or enclosed are being deposited with the United States Postal Service on this date, March 13, 2002, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, Express Mail Label No. EL 778 572 141 US, addressed to Box Patent Application, Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Pam Turnbough
Pam Turnbough

Date: March 13, 2002

ATL1 #512571 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. PATENT DOCUMENTS

Examine Signature		Date Considered
----------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	Continuation of 09/445,865
Sheet	2	of	9	Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number
				March 13, 2002 Philip John Burke Examiner Name ERD 100 CON

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)			
		EP	0 251 744	A2	Delta Biotechnology Ltd.	01-07-1988	
		EP	0 258 067	A2	Delta Biotechnology Ltd.	03-02-1988	
		EP	0 302 473	A2	Bristol-Myers Co.	02-08-1989	
		EP	0 415 731	A2	The Wellcome Foundation Ltd.	03-06-1991	
		WO	88/07378	A1	Cancer Research Campaign Technology Ltd.	10-06-1988	
		WO	89/10140	A1	Cancer Research Campaign Technology Ltd.	11-02-1989	
		WO	90/01063	A1	Delta Biotechnology Ltd.	02-08-1990	
		WO	91/09867	A1	Imperial Cancer Research Technology Ltd.	07-11-1991	
		WO	91/11201	A1	Imperial Cancer Research Technology Ltd.	08-07-1991	
		WO	93/08288	A1	Cancer Research Campaign Technology Ltd.	04-29-1993	
		WO	93/13805	A1	Bagshawe	07-22-1993	
		WO	93/13806	A1	Bagshawe	07-22-1993	
		WO	95/12678	A1	Cancer Research Campaign Technology Ltd.	05-11-1995	
		WO	97/07097	A1	Auckland Division Cancer Society of New Zealand	02-27-1997	
		WO	97/24143	A1	AEPACT, Ltd.	07-10-1997	
		WO	97/20580	A1	AEPACT, Ltd.	06-12-1997	
		WO	97/24143	A1	AEPACT, Ltd.	07-10-1997	
		WO	98/22577	A1	Masucci	05-28-1998	
		WO	98/24478	A2	AEPACT, Ltd.	06-11-1998	

Examinee Signature		Date Considered
-----------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation f 09/445,865
Sheet	3	of	9
		Attorney Docket Number	ERD 100 CON

OTHER ART – NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		ANLEZARK, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from <i>Escherichia coli</i> —a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)," <i>Biochem. Pharmacol.</i> 1992 44(12):2289-95.
		BETTER, et al., "Escherichia coli secretion of an active chimeric antibody fragment," <i>Science</i> 240(4855):1041-43 (1988).
		BIRD, et al., "Single-chain antigen-binding proteins," <i>Science</i> 242(4877):423-26 (1988).
		BISCHOFF, et al., "An adenovirus mutant that replicates selectively in p53-deficient human tumor cells," <i>Science</i> 274(5286):373-76 (1996).
		BOLAND, et al., "The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)," <i>Biochem. Pharmacol.</i> 41(6-7):867-75 (1991).
		BRADL, et al., "Malignant melanoma in transgenic mice," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 88(1):164-68 (1991).
		BRAWER, "Prostate specific antigen. A review," <i>Acta. Oncol.</i> 30(2):161-68 (1991).
		CHEN, et al., "Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in <i>Escherichia coli</i> and mutagenesis in vitro at Arg-177," <i>Biochem. J.</i> 284 (Pt 3):855-60 (1992).
		CHEN, et al., "Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse," <i>J. Biol. Chem.</i> 272(3):1437-39 (1997).
		CLARK, et al., "Role of the Bp35 cell surface polypeptide in human B-cell activation," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 82(6):1766-70 (1985).

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/445,865
		Filing Date	March 13, 2002
		First Named Inventor	Philip John Burke
		Group Art Unit	
Sheet	4	of	9
		Attorney Docket Number	ERD 100 CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CONNORS & WISSON, "Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity," <i>Nature</i> 210(38):866-67 (1966).	
		CORVALAN & SMITH, "Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," <i>Cancer Immunol. Immunother.</i> 24(2):127-32 (1987).	
		CORVALAN, et al., "Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody," <i>Cancer Immunol. Immunother.</i> 24(2):138-43 (1987).	
		CORVALAN, et al., "Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," <i>Cancer Immunol. Immunother.</i> 24(2):133-37 (1987).	
		COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 89(13):6094-98 (1992).	
		COUSSENS, et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene," <i>Science</i> 230(4730):1132-39 (1985).	
		CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," <i>Science</i> 256(5063):1550-52 (1992).	
		CURIEL, "Adenovirus facilitation of molecular conjugate-mediated gene transfer," <i>Prog. Med. Virol.</i> 40:1-18 (1993).	
		DERMER, "Another Anniversary for the War on Cancer," <i>Bio/Technology</i> 12:230 (1994).	
		DRABEK, et al., "The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954," <i>Gene Ther.</i> 4(2):93-100 (1997).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/445,865
Sheet	5	of	9
		Attorney Docket Number	ERD 100 CON

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FRESHNEY, <i>Culture of Animal Cells: A Manual of Basic Technique</i> , Alan R. Liss, Inc., page 4, (New York, 1983).	
		FRIEDLOS & KNOX, "Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system," <i>Biochem. Pharmacol.</i> 44(4):631-35 (1992).	
		FRIEDLOS, et al., "Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)," <i>Biochem. Pharmacol.</i> 44(1):25-31 (1992).	
		FRIEDLOS, et al., "Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity," <i>Biochem. Pharmacol.</i> 44(9):1739-43 (1992).	
		GILLILAND, et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 85(20):7719-23 (1988).	
		GREEN, et al., "Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the <i>E. coli</i> nitroreductase gene," <i>Cancer Gene Ther.</i> 4(4):229-38 (1997).	
		GURA, "Systems for Identifying New Drugs are Often Faulty," <i>Science</i> 278:1041-42 (1997).	
		HARWOOD, et al., "Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumour xenograft," <i>Eur. J. Cancer Clin. Oncol.</i> 21(12):1515-22 (1985).	
		HELLSTRÖM, et al., "Monoclonal mouse antibodies raised against human lung carcinoma," <i>Cancer Res.</i> 46(8):3917-23 (1986).	
		HURRELL, "Monoclonal Hybridoma Antibodies: Techniques and Applications," (CRC Press).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/445,865
Sheet	6	of	9
		Attorney Docket Number	ERD 100 CON

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		HUSTON, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 85(16):5879-83 (1988).	
		JACKSON, et al., "The tyrosinase-related protein-1 gene has a structure and promoter sequence very different from tyrosinase," <i>Nucleic Acids Res.</i> 19(14):3799-804 (1991)	
		JAISWAL, "Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression," <i>J. Biol. Chem.</i> 269(20):14502-08 (1994).	
		JAISWAL, "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6," <i>Biochemistry</i> , 29(7):1899-906 (1990).	
		KHAN & ROSS, "Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships," <i>Chem. Biol. Interact.</i> 1(1):27-47 (1969).	
		KNOX, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-II. A comparison of an <i>Escherichia coli</i> nitroreductase and Walker DT diaphorase," <i>Biochem. Pharmacol.</i> 44(12):2297-301 (1992).	
		KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," <i>Cancer Metastasis Rev.</i> 12(2):195-212 (1993).	
		KNOX, et al., "Virtual cofactors for an <i>Escherichia coli</i> nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," <i>Biochem. Pharmacol.</i> 49(11):1641-47 (1995).	
		KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," <i>Cell Struct. Funct.</i> 16(6):503-10 (1991).	
		LAEMMLI, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," <i>Nature</i> 227(259):680-5 (1970).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/445,865
Sheet	7	of	9
		Attorney Docket Number	ERD 100 CON

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LEDLEY, "Nonviral gene therapy: the promise of genes as pharmaceutical products," <i>Hum. Gene Ther.</i> 6(9):1129-44 (1995).	
		LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," <i>Biochem. and Biophys. Res. Comm.</i> 4:208-13 (1961).	
		LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic hydrocarbons," <i>Biochem. Pharmacol.</i> 6:53-54 (1961).	
		LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide," <i>J. Biol. Chem.</i> 237:2981-87 (1962).	
		LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," <i>Biochem. Biophys. Res. Commun.</i> 161(3):1151-9 (1989).	
		MARTIN & PAPAHAJOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting," <i>J. Biol. Chem.</i> 257(1):286-8 (1982).	
		MAUGER, et al., "Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme," <i>J. Med. Chem.</i> 37(21):3452-58 (1994).	
		MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," <i>Gene Ther.</i> 2(9):660-68 (1995).	
		MILLER & VILE, "Targeted vectors for gene therapy," <i>FASEB J.</i> 9(2):190-99 (1995).	
		MORRISON, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 81(21):6851-55 (1984).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/445,865
Sheet	8	of	9
		Attorney Docket Number	ERD 100 CON

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		NASSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice," <i>Cancer Res.</i> 52(3):646-53 (1992).	
		NEUBERGER, et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> 312(5995):604-08 (1984).	
		O'SULLIVAN, et al., "Comparison of two methods of preparing enzyme-antibody conjugates: application of these conjugates for enzyme immunoassay," <i>Anal. Biochem.</i> 100(1):100-08 (1979).	
		QUINN, "Studies on CB1954 and its analogues," A thesis submitted for the degree of Doctor of Philosophy to the University of London, 1996.	
		RIEGMAN, et al., "Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene," <i>Biochem. Biophys. Res. Commun.</i> 159(1):95-102 (1989).	
		SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase," <i>Science</i> 239(4839):487-91 (1988).	
		SAMBROOK, et al., <i>Molecular Cloning: A Laboratory Manual</i> Cold Spring Harbor Laboratory Press, Cold Spring Harbor:New York (1989).	
		SCHREWE, et al., "Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression," <i>Mol. Cell. Biol.</i> 10(6):2738-48 (1990).	
		SHARMA, et al., "Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model," <i>Br. J. Cancer.</i> 61(5):659-62 (1990).	
		SHERWOOD, "Advanced drug delivery reviews: enzyme prodrug therapy," <i>Adv. Drug Del. Rev.</i> 22:269-88 (1996).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Continuation of 09/445,865
Sheet	9	of	9	Filing Date	March 13, 2002
				First Named Inventor	Philip John Burke
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	ERD 100 CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SKERRA, et al., "Assembly of a functional immunoglobulin Fv fragment in Escherichia coli," <i>Science</i> 240(4855):1038-41 (1988).	
		TROWELL, "The cytoidal action of mitotic poisons on lymphocytes <i>in vitro</i> ," <i>Biochemical Pharmacology</i> 5:53-63 (1960).	
		WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 87(9):3410-14 (1990).	
		WARD, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," <i>Nature</i> 341(6242):544-46 (1989).	
		WHISSON & CONNORS, "Cure of mice bearing advanced plasma cell tumours with aniline mustard," <i>Nature</i> 206(985):689-91 (1965).	
		WINTER & MILSTEIN, "Man-made antibodies," <i>Nature</i> 349(6307):293-99 (1991).	
		WU, et al., "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase," <i>Arch. Biochem. Biophys.</i> 347(2):221-28 (1997).	
		ZOLA, "Monoclonal Antibodies: A manual of techniques," (CRC Press, 1988).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+